Ovid Therapeutics (OVID) - 2025 Q4 - Annual Report
Ovid Therapeutics (US:OVID)2026-03-18 20:25UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the Fiscal Year Ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-38085 __________________________________ Ovid Therapeutics Inc. FORM 10-K _________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 _________________________________ ...